Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Production Capacity Integration + Energy Independence, Blue Sail Medical's Glove Business Turnaround Expected
Recently, Blue Sail Medical (002382.SZ) announced that two key acquisitions by its subsidiary, Shandong Blue Sail Health Technology Co., Ltd. (referred to as “Shandong Health Tech”), have been successfully completed. Not only did they acquire 100% equity in Zibo Blue Sail Health Tech Co., Ltd. and Zibo Blue Sail Protective Products Co., Ltd. (“Zibo Health Tech, Zibo Protective”), but they also secured an 80% stake in Zibo Hongda Thermal Power Co., Ltd. (“Hongda Thermal Power”). These two projects work synergistically to achieve dual breakthroughs: integrating glove production capacity and offsetting energy costs. This provides strong momentum for a turnaround in Blue Sail Medical’s core glove business, with ongoing performance flexibility expected to be released.
The announcement indicates that both acquisitions were driven by a $200 million capital increase funded by a Thai industrial investor, not using Blue Sail Medical’s own funds. This alleviates the company’s cash flow pressure and allows for precise business layout upgrades. Specifically, Shandong Health Tech acquired 100% equity in Zibo Health Tech and Zibo Protective for 800 million yuan, aiming to revitalize nitrile glove resources, transforming the industry’s supply-demand imbalance from “new capacity addition” to “resource integration” to improve operational efficiency. This move is expected to significantly enhance the overall competitiveness and profitability of the nitrile glove business. After the transaction, Shandong Health Tech will centrally manage all of Blue Sail Medical’s nitrile glove resources, forming three major production bases with an annual capacity of approximately 25 billion gloves. The unified management of health protection products will create synergies in equipment deployment, process optimization, and supply chain management, with operational efficiency expected to continue improving.
Alongside capacity integration, addressing energy supply shortages has become another key breakthrough. Shandong Health Tech acquired an 80% stake in Hongda Thermal Power for 400 million yuan, primarily to systematically address energy supply gaps at Zibo’s nitrile glove production base and establish an independent, controllable energy security system. As the only heat source center in its park, it can provide stable, low-cost electricity and heat to Blue Sail’s own glove factories. Additionally, thanks to the capital increase from Thailand, Shandong Health Tech obtained a rare combined heat and power (CHP) approval, with related units expected to start operation in Q2 2026, utilizing excess heat from glove production for power generation and grid sales. These positive factors enable the company to implement CHP in both Zibo and Weifang, further expanding cost advantages. The ongoing growth of the glove business will bring additional profit growth points for Blue Sail Medical.
By Q4 2025, the gross profit margin of the glove business has successfully turned positive, and the health protection segment is expected to be the most significant driver of performance recovery in 2026. Currently, the company’s nitrile glove capacity is fully utilized and sold out, while exports of PVC gloves have surged since October 2025, laying a solid foundation for price increases in these two major glove categories.
Amid multiple positive factors, the turnaround of Blue Sail Medical’s glove business is becoming increasingly clear. Currently, under the influence of global geopolitical factors, the prices of core raw materials for gloves have risen sharply, entering a cycle of price increases. Meanwhile, the company’s precise prediction of raw material price trends, through strategic phased procurement and price locking, has essentially locked in raw material costs through the first half of 2026, successfully avoiding cost pressures from this round of raw material price surges.
Furthermore, the company has two unique advantages in raw material security. First, its controlling shareholder’s chemical division is a leading enterprise in plasticizers and resin adhesives nationwide, with annual revenue exceeding 10 billion yuan, and is a major supplier of raw materials for PVC gloves. Second, its Thai industrial investor owns over 200,000 tons of nitrile latex capacity, which can provide reasonably priced and stable nitrile latex resources in extreme market conditions.
Historical experience shows that the end prices of gloves tend to increase more than raw material prices, especially in the current industry cleanup and return of pricing power to leading companies. Price increases at the end market are more transmissible, and the company is expected to leverage its raw material cost-locking advantage to fully benefit from industry price hikes, achieving rapid profit recovery.
Meanwhile, the company’s glove production line upgrades are progressing in phases. The Weifang plant completed its upgrade when first investing in Thailand in 2024, reaching advanced standards; by the end of 2025, both Zibo bases will have completed upgrades, significantly improving production efficiency and cost control. By reducing energy costs through acquisitions of thermal power plants and upgrading production lines, combined with the release of integration dividends and industry recovery opportunities, there remains considerable room for gross profit margin improvement in the glove business. Blue Sail Medical is poised for potentially exceeding performance expectations.
(Edited by: Wang Lei)
【Disclaimer】This article reflects only third-party opinions and does not represent Hexun’s position. Investors operate at their own risk.
【Advertisement】This article only represents the author’s personal views and is not affiliated with Hexun. Hexun’s website remains neutral regarding the statements and opinions expressed and does not guarantee the accuracy, reliability, or completeness of the content. Readers should use it for reference only and bear all responsibilities themselves. Email: news_center@staff.hexun.com